Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(10):803–809. doi: 10.1111/j.1349-7006.2004.tb02185.x

Activation of c‐Met (hepatocyte growth factor receptor) in human gastric cancer tissue

Takao Inoue 1,5, Hiroaki Kataoka 2,5, Kouichiro Goto 3, Koki Nagaike 2, Ko Igami 4, Daiji Naka 4, Naomi Kitamura 1, Keiji Miyazawa 1,5,✉
PMCID: PMC11158965  PMID: 15504247

Abstract

c‐Met is a high‐affinity receptor for hepatocyte growth factor (HGF) and plays a crucial role in embryonic development, as well as in the process of tissue repair. Overexpression and amplification of c‐Met are often observed in various cancer tissues, especially in gastric carcinoma. It has, however, been unclear whether the overexpression leads to activation of the c‐Met receptor. To address this point, we prepared an antibody (anti‐phospho‐Met) which specifically recognizes c‐Met that is phosphorylated at Y1235, a major phosphorylation site of c‐Met. Normal as well as cancerous gastric tissue was positive for anti‐total‐Met staining, whereas only cancerous tissue was strongly positive for anti‐phospho‐Met staining; cells near the basal layer were moderately positive, and the proliferative zone in normal tissue was only weakly positive. Among cancerous tissues from seven patients examined in the present study, those from six patients were strongly positive for phospho‐Met staining. These results indicate that c‐Met is actually activated in gastric carcinoma tissue, and may trigger proliferation/anti‐apoptotic signals.

References

  • 1. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 29–33. [DOI] [PubMed] [Google Scholar]
  • 2. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude GF. Sequence of MET protooncogene cDNA has features characteristic of the ty‐rosine kinase family of growth‐factor receptors. Proc Natl Acad Sci USA 1987; 84: 6379–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Ponzetto C, Giordano S, Peverali F, Delia Valle G, Abate ML, Vaula G, Comoglio PM. c‐met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991; 6: 553–9. [PubMed] [Google Scholar]
  • 4. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson A. Identification of the hepatocyte growth factor receptor as the c‐met proto‐oncogene product. Science 1991; 251: 802–4. [DOI] [PubMed] [Google Scholar]
  • 5. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartman G, Zarnegar R, Michalopoulos GK, Birchmeier W, Comoglio PM. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991; 10: 2867–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Komada M, Miyazawa K, Ishii T, Kitamura N. Characterization of hepato‐cyte‐growth‐factor receptors on Meth A cells. Eur J Biochem 1992; 204: 857–64. [DOI] [PubMed] [Google Scholar]
  • 7. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c‐met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995; 376: 768–71. [DOI] [PubMed] [Google Scholar]
  • 8. Danilkovitch‐Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109: 863–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Schmidt L, Duh F‐M, Chen F, Kishida T, Glenn G, Choyke P, Scherer S, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim U, Feltis T, Casadevall C, Zamarron A, Bemues M, Richad S, Lips CMJ, Walther MM, Tsui L‐C, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto‐oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68–73. [DOI] [PubMed] [Google Scholar]
  • 10. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY Somatic mutations in the kinase domain of the Met/ hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999; 59: 307–10. [PubMed] [Google Scholar]
  • 11. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19: 4947–53. [DOI] [PubMed] [Google Scholar]
  • 12. Komada M, Kitamura N. Regulatory role of major tyrosine autophosphoryla‐tion site of kinase domain of c‐Met receptor (scatter factor/hepatocyte growth factor receptor). J Biol Chem 1994; 269: 16131–6. [PubMed] [Google Scholar]
  • 13. Tsukada Y, Miyazawa K, Kitamura N. High intensity ERK signal mediates hepatocyte growth factor‐induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 2001; 276: 40968–76. [DOI] [PubMed] [Google Scholar]
  • 14. Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein‐tyrosine kinases. J Biol Chem 1998; 273: 11987–90. [DOI] [PubMed] [Google Scholar]
  • 15. Ferracini R, Longati P, Naldini L, Vigna E, Comoglio PM. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 1991; 266: 19558–64. [PubMed] [Google Scholar]
  • 16. Naldini L, Vigna E, Ferracini R, Longati P, Gandino L, Prat M, Comoglio PM. The tyrosine kinase encoded by the MET proto‐oncogene is activated by autophosphorylation. Mol Cell Biol 1991; 11: 1793–803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Chiara F, Michieli P, Pugliese L, Comoglio PM. Mutations in the met onco‐gene unveil a “dual switch” mechanism controlling tyrosine kinase activity. J Biol Chem 2003; 278: 29352–8. [DOI] [PubMed] [Google Scholar]
  • 18. Miyazawa K, Kitamura A, Naka D, Kitamura N. An alternatively processed mRNA generated from human hepatocyte growth factor gene. Eur J Biochem 1991; 197: 15–22. [DOI] [PubMed] [Google Scholar]
  • 19. Naka D, Ishii T, Miyazawa K, Hara H, Hishida T, Kitamura N. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem 1992; 267: 20114–9. [PubMed] [Google Scholar]
  • 20. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 2000; 60: 6148–59. [PubMed] [Google Scholar]
  • 21. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001; 153: 1023–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol 2002; 4: 720–4. [DOI] [PubMed] [Google Scholar]
  • 23. Kinoshita Y, Nakata H, Hassan S, Asahara M, Kawanami C, Matsushima Y, Naribayashi‐Inomoto Y, Ping CY, Min D, Nakamura A, Chiba T. Gene expression of keratinocyte and hepatocyte growth factor during the healing of rat gastric mucosal lesions. Gastroenterology 1995; 109: 1068–77. [DOI] [PubMed] [Google Scholar]
  • 24. Schmassmann A, Stettler C, Poulsom R, Tarasova N, Hirschi C, Flogeri B, Matsumoto K, Nakamura T, Halter F. Roles of hepatocyte growth factor and its receptor Met during gastric ulcer healing in rats. Gastroenterology 1997; 113: 1858–72. [DOI] [PubMed] [Google Scholar]
  • 25. Churin Y, Al‐Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M. Helicobacter pylori CagA protein targets the c‐Met receptor and enhances the motogenic response. J Cell Biol 2003; 161: 249–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anti‐cancer drugs. Trends Mol Med 2002; 8: 17–23. [DOI] [PubMed] [Google Scholar]
  • 27. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB. A selective small molecule inhibitor of c‐Met kinase inhibits c‐Met‐dependent phenotypes in vitro and exhibits cytoreduc‐tive antitumor activity in vivo . Cancer Res 2003; 63: 7345–55. [PubMed] [Google Scholar]
  • 28. Matsumoto K, Nakamura T. NK4 (HGF‐antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94: 321–7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES